Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful. Also disclosed are methods of making the compounds.

The present invention relates to a ligand compound, a catalyst system for olefin oligomerization, and a method for oligomerizing olefins using the same. The ligand compound according to the present invention has a structure in which a substituent is substituted in the trans form, and thereby when used for olefin oligomerization, the activity of the catalyst used and the selectivity of 1-hexene and 1-octene can be increased.

The present invention relates to a ligand compound, a catalyst system for olefin oligomerization, and a method for oligomerizing olefins using the same. The ligand compound according to the present invention has a structure in which a substituent is substituted in the trans form, and thereby when used for olefin oligomerization, the activity of the catalyst used and the selectivity of 1-hexene and 1-octene can be increased.

A flame-retardant aconitic acid-derived small molecule, a process for forming a flame-retardant polymer, and an article of manufacture comprising a material that contains a flame-retardant aconitic acid-derived small molecule are disclosed. The flame-retardant aconitic acid-derived small molecule can be synthesized from aconitic acid obtained from a bio-based source, and can have at least one phosphoryl or phosphonyl moiety with phenyl, allyl, or thioether substituents. The process for forming the flame-retardant polymer can include reacting an aconitic acid derivative with a flame-retardant phosphorus-based molecule to form a flame-retardant aconitic acid-derived small molecule, and combining the flame-retardant aconitic acid-derived small molecule with a polymer. The material in the article of manufacture can be a resin, adhesive, polymer, etc.

The invention relates to stereospecific lipids for the locoregional therapy with long-term circulating stimuli-sensitive nanocarrier systems. A preferred embodiment thereof is a thermosensitive liposome for treating tumors, especially urinary bladder tumors and other localized tumors.

A method for manufacturing a phosphate, which includes reacting, in a solvent, an organophosphate represented by the following formula (2) and an alkali metal hydroxide in an amount of 1.01 mole equivalents or more relative to the organophosphate to provide a composition containing a phosphate represented by the following formula (1), the alkali metal hydroxide, and the solvent; and adding hydrogen fluoride to the composition to neutralize the composition and to precipitate an alkali metal fluoride, thereby providing a composition containing the precipitated alkali metal fluoride, the phosphate represented by the formula (1), and the solvent. The formula (1) is (R.sup.11O)(R.sup.12O)PO.sub.2M, where R.sup.11, R.sup.12 and M are as defined herein. The formula (2) is (R.sup.21O)(R.sup.22O)(R.sup.23O)PO, where R.sup.21, R.sup.22, and R.sup.23 are as defined herein.

The present invention relates to a ligand compound, a catalyst system for olefin oligomerization and a method for oligomerizing an olefin using same. The catalyst system for olefin oligomerization according to the present invention exhibits high selectivity to 1-hexene or 1-octene while having excellent catalytic activity, thus enabling more efficient preparation of alpha-olefins.

Disclosed are compounds including phosphate and N-oxide prodrugs of the NK1 antagonist netupitant, useful in the prevention and/or treatment of diseases including emesis induced by chemotherapy. Also disclosed are methods of making a di-tert-butyl (chloromethyl) phosphate useful in the manufacture of such prodrugs by reacting a dialkylphosphate salt with an acid to obtain the corresponding ester of phosphoric acid, reacting the ester with a quaternary ammonium hydroxide base to form a monobasic salt, and reacting the monobasic salt with chloroiodomethane to form the corresponding chloromethyl dialkyl phosphate. ##STR00001##

The present invention relates to a ligand compound, a catalyst system for olefin oligomerization, and a method for oligomerizing olefins using the same. The ligand compound according to the present invention has a structure in which a substituent is substituted in the trans form, and thereby when used for olefin oligomerization, the activity of the catalyst used and the selectivity of 1-hexene and 1-octene can be increased.

The development of anticancer metal-based drugs was done by reacting oyelamine with selenous acid to produce a quaternary ammonium salt which consequently converted to platinum and cobalt cationic complexes via complexing the first compounds with platinum (II) or cobalt (II) ions. The surface properties studies that were conducted included critical micelle concentration (CMC), maximum surface excess (max) and minimum surface area (Amin). Free energy of micellization (G mic) and adsorption (G ads) were calculated. Antitumor activities were tested by using Ehrlich Acites Carcinoma (EAC) as a model system of mice cell tumor. These compounds were also tested in vitro on human five monolayer tumor cell lines: MCF7 (Breast carcinoma), HEPG2 (liver carcinoma), and HCT116 (colon carcinoma), etc. FTIR spectra, elemental analysis and H1 NMR spectrum were performed to insure the purity of the prepared compounds.